5-Amino-1MQ Research Overview (also known as 5-amino-1-methylquinolinium, 5-amino-1MQ, NNMT inhibitor)
A small molecule inhibitor of NNMT (Nicotinamide N-Methyltransferase), an enzyme involved in regulating cellular metabolism and fat storage. Research in animal models has shown 5-Amino-1MQ to support fat-loss pathways, improve insulin sensitivity, and enhance cellular energy output. Studied primarily in the context of metabolic syndrome, obesity, and stubborn-fat reduction.
What Is 5-Amino-1MQ?
5-Amino-1-methylquinolinium (5-Amino-1MQ) is a small-molecule inhibitor of Nicotinamide N-Methyltransferase (NNMT) — an enzyme that consumes SAM (S-adenosylmethionine) to methylate nicotinamide, producing 1-methylnicotinamide and reducing cellular NAD+ availability. By blocking NNMT, 5-Amino-1MQ raises intracellular NAD+ and SAM levels, activating longevity-associated metabolic pathways.
Mechanism of Action
NNMT is highly expressed in white adipose tissue and acts as a metabolic rheostat — high NNMT activity correlates with obesity, insulin resistance, and reduced cellular energy expenditure. By inhibiting NNMT, 5-Amino-1MQ shifts adipose tissue toward a more metabolically active state: increased mitochondrial biogenesis, enhanced fatty acid oxidation, and activation of SIRT1 and other NAD+-dependent enzymes including PARPs and CD38.
Fat Loss and Metabolic Research
In animal studies, 5-Amino-1MQ administration produced significant reductions in fat mass without changes in lean body mass or food intake. Treated animals showed increased energy expenditure, improved glucose tolerance, and reduced adipocyte size — effects occurring at doses that produced no observable toxicity.
Comparison with NMN/NR
While NMN and NR raise NAD+ by providing precursors, 5-Amino-1MQ raises NAD+ by reducing its consumption — a complementary mechanism that some researchers combine with NAD+ precursor supplementation for potentially additive effects on cellular NAD+ levels.
Quick Reference
| Literature-Reported Dose Range | 50-75mg |
| Literature-Reported Frequency | Once daily with food |
| Literature-Reported Cycle Length | 8-12 weeks |
| Literature-Reported Washout | 2-4 weeks off |
| Storage | Cool, dry place |
| Sites Reported in Studies | Oral capsules (take with meals) |
| Timing | With breakfast or lunch |
Research Indications
Longevity
NAD+ Enhancement
Significantly increases cellular NAD+ levels by inhibiting NNMT, supporting cellular energy production and DNA repair mechanisms
Mitochondrial Function
Improves mitochondrial biogenesis and efficiency, enhancing cellular energy production and reducing oxidative stress
Cellular Repair
Enhanced NAD+ availability supports sirtuins and other longevity pathways involved in DNA repair and cellular maintenance
Metabolism
Energy Metabolism
Improves cellular energy production through enhanced mitochondrial function and more efficient glucose and fatty acid utilization
Insulin Sensitivity
May improve insulin sensitivity and glucose metabolism through enhanced cellular energy processes
Fat Oxidation
Potentially enhances fat burning and metabolic flexibility through improved mitochondrial function
Weight Loss
Metabolic Enhancement
Increases basal metabolic rate and helps body burn fat for energy while maintaining muscle mass preferentially
Fat Cell Reduction
Mouse studies (PMC5826726) show 30% adipocyte size reduction at 60mg/kg/day
Energy Balance
Shifts body's energy balance toward burning fat rather than storing it, particularly beneficial for obesity
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| General longevity support | 50mg | 1x daily | Oral (with food) |
| Enhanced metabolic function | 75mg | 1x daily | Oral (with food) |
| Maximum NAD+ enhancement | 100mg | 1x daily | Oral (with food) |
| Conservative approach | 25mg | 1x daily | Oral (with food) |
Timing
Recommended administration window: with breakfast or lunch. Typical onset: energy: 1-2 weeks, Metabolic: 4-8 weeks.
Peptide Interactions
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
May work synergistically with NAD+ precursors by preventing breakdown while supporting production
Both support longevity pathways; resveratrol activates sirtuins while 5-Amino-1MQ provides NAD+ substrate
Both affect metabolic pathways; combination may enhance effects but requires careful monitoring
No known interactions; different mechanisms of action with potential complementary benefits
Limited interaction data; consult healthcare provider before combining with anticoagulants
Both affect metabolic pathways; potential additive effects on glucose metabolism
Reported Research Timeline
01Week 1–2 (reported in cited studies): gradual increase in energy levels and mental clarity
02Week 2–4 (reported in cited studies): enhanced exercise performance and recovery
03Week 4–8 (reported in cited studies): improved metabolic markers and body composition
04Week 8–12 (reported in cited studies): sustained longevity benefits and cellular health
05Most effective for: Metabolic health, longevity, energy enhancement
Side effects (reported in cited studies): generally minimal, occasional mild GI adjustment
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
NO human clinical trials exist - all dosing from animal extrapolation
Community SubQ practice is approximately 2-5mg/day (Tier 4: PeptideDosages.com and independent user reports). The 50-100mg figure referenced elsewhere is an allometric oral HED derived from mouse SC data (Neelakantan 2018, PMC5826726) via FDA Km scaling. It is not a validated SubQ dose. No human pharmacokinetic data exists for any injectable dose.
Start with lowest effective dose (25-50mg oral) to assess tolerance
Take with food to reduce potential GI effects
Monitor for any unusual symptoms and discontinue if adverse effects occur
Not recommended for pregnant or breastfeeding women
Consult healthcare provider before use
Seek Medical Attention If:
Severe gastrointestinal upset or persistent nausea
Unusual fatigue or weakness (opposite of expected effect)
Persistent headaches or dizziness
Sleep disturbances or insomnia
Any allergic reactions (rash, swelling, difficulty breathing)
Any concerning symptoms that don't resolve quickly
Quality Indicators
Verified Marker
Orange to amber-colored powder
5-Amino-1MQ commonly appears as orange to amber colored powder. Color consistency within batch is important
Verified Marker
Third-party testing certificates
Reputable suppliers provide COA with purity analysis (should be >98% pure) and heavy metal testing
Verified Marker
Proper pharmaceutical packaging
Sealed bottles with moisture protection, clear expiration dates, and professional labeling
Quality Concern
Moisture damage or clumping
Capsules should not be sticky, discolored, or show signs of moisture exposure or heat damage
Quality Concern
Unusual odor or appearance
Should be relatively odorless; strong chemical odors may indicate contamination or degradation
Research Citations
Research Focus
Mitochondrial biogenesis, NAD+ metabolism, Fat loss, Metabolic health, NNMT inhibition
Verified Vendors Carrying 5-Amino-1MQ
Frequently Asked Questions
What should researchers watch for with 5-Amino-1MQ?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with 5-Amino-1MQ?
Week 1–2 (reported in cited studies): gradual increase in energy levels and mental clarity
How is 5-Amino-1MQ typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →